Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Up 85.2% in May

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the target of a large growth in short interest in May. As of May 15th, there was short interest totaling 14,337 shares, a growth of 85.2% from the April 30th total of 7,742 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 20,059 shares, the days-to-cover ratio is currently 0.7 days.

Barinthus Biotherapeutics Stock Up 0.5%

Barinthus Biotherapeutics stock opened at $0.68 on Tuesday. The firm has a 50-day moving average price of $0.63 and a two-hundred day moving average price of $0.67. The firm has a market capitalization of $27.94 million, a price-to-earnings ratio of -0.53 and a beta of -0.40. Barinthus Biotherapeutics has a 52-week low of $0.51 and a 52-week high of $2.92.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.14.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in BRNS. Rangeley Capital LLC grew its position in Barinthus Biotherapeutics by 88.8% in the first quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock worth $91,000 after acquiring an additional 75,024 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Barinthus Biotherapeutics by 115.8% during the 4th quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after buying an additional 76,800 shares during the period. Finally, Baird Financial Group Inc. boosted its holdings in shares of Barinthus Biotherapeutics by 108.2% during the 2nd quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after buying an additional 100,000 shares during the period. Institutional investors and hedge funds own 25.20% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $4.00.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.